Keith Kerman, M.D. is an Operating Partner and Senior Advisor with The Riverside Company, a global private equity firm focused on investing in growth businesses valued at up to $250 million. Dr. Kerman joined Riverside in 2012 and focuses his activity on the firm's healthcare activity. He has 20 years of experience in private equity and operating roles, and has been an executive, investor, and board member in a broad range of healthcare related businesses and organizations.
Prior to joining Riverside, Dr. Kerman was a Managing Director and led the healthcare practice at Primus Capital Funds, a growth equity and middle market buyout firm, and was previously a General Partner with Morgenthaler Ventures. Previously, Dr. Kerman was an operating executive at U.S. Healthcare, where he was president of the company's subsidiary providing managed care services to self-funded health plans. Dr. Kerman was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, a member of the clinical faculty at the Hospital of the University of Pennsylvania, and was a Senior Fellow at the Leonard Davis Institute for Health Economics at The Wharton School. He has an AB and an MD from Brown University, and an MBA from The Wharton School of the University of Pennsylvania.
Dr. Kerman currently serves on the Board of Directors of AxioMed Spine Corporation, Physicians Pharmacy Alliance, and IDOC. He also serves on the worldwide Board of Directors of the Healthcare Information Management Systems Society (HIMSS), is a member of the Cleveland Clinic Innovations Advisory Board, and is Chairman of the Advisory Board of the Cleveland Clinic's Global Cardiology Innovation Center. .